Patent cliffs aren’t just a legal event—they’re a supply-chain event.
When a blockbuster drug’s exclusivity ends, the industry often treats it like a spreadsheet problem: update forecasts, watch for generic launches, and move on. But the real impact …

Generic drug margins are under siege—and it’s not just one villain. It’s a whole cast of pressures hitting at once: pricing pressure that never really lets up, reimbursement uncertainty, manufacturing complexity, regulatory friction, and the growing re…

Branded pharma’s revenue model is under siege—and the threats aren’t subtle.
If you’re a brand-name drug company, the last decade has trained you to expect “normal” headwinds: patent cliffs, payer pressure, and competitive launches. But the reality is …

Generic drug makers don’t “guess” when they can launch. They read the FDA’s Orange Book like a map—and then they move fast.
If you’ve ever wondered how some generic manufacturers seem to time market entry with surgical precision, the answer isn’t luck….

Biopharma hiring is broken in a subtle way: we keep treating IP as a “legal function” instead of an operating system.
If you’ve ever wondered why two companies with similar patent counts can look wildly different in how they build pipelines, launch pro…

The Generic Cliff Isn’t a Cliff—It’s a Deadline. Here’s How Pharma Engineers Around It.
If you’ve ever watched a blockbuster drug’s patent clock run down, you’ve seen the headlines: “Generic approval imminent,” “price erosion begins,” “revenue at risk….

Patent thickets are the new moat—and biologics are the new battleground.
If you’ve ever wondered why some blockbuster biologic drugs seem to “never really go generic,” the answer is often not science—it’s strategy. Drug Patent Watch’s deep dive into …

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you “deal with later”—after you’ve invested in manufacturing, clinical trials, or market entry. But in pharma, waiting is expensive. The r…

Most teams look at drug patents the wrong way.
They read claims. They track expiration dates. They wait for litigation signals.
But formulation patents—often the most “quiet” IP in a portfolio—can quietly decide whether a generic, biosimilar, or fo…

Russia’s latest VED/SSM list update is a reminder that “generic timing” is no longer just a U.S. or EU exercise—it’s a global discipline. The market isn’t waiting for your internal calendar. It’s moving to the rhythm of patent expirations, regulatory s…